Logo image of CDIO

CARDIO DIAGNOSTICS HOLDINGS (CDIO) Stock Price, Quote, News and Overview

NASDAQ:CDIO - Nasdaq - US14159C1036 - Common Stock - Currency: USD

4.31  +0.06 (+1.41%)

After market: 4.21 -0.1 (-2.32%)

CDIO Quote, Performance and Key Statistics

CARDIO DIAGNOSTICS HOLDINGS

NASDAQ:CDIO (5/28/2025, 8:24:42 PM)

After market: 4.21 -0.1 (-2.32%)

4.31

+0.06 (+1.41%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High53.1
52 Week Low3.4
Market Cap7.50M
Shares1.74M
Float1.61M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-12 2025-08-12
IPO11-23 2021-11-23


CDIO short term performance overview.The bars show the price performance of CDIO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

CDIO long term performance overview.The bars show the price performance of CDIO in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of CDIO is 4.31 USD. In the past month the price decreased by -68.47%. In the past year, price decreased by -79.26%.

CARDIO DIAGNOSTICS HOLDINGS / CDIO Daily stock chart

CDIO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.83 323.41B
AMGN AMGEN INC 13.41 149.70B
GILD GILEAD SCIENCES INC 14.01 134.89B
VRTX VERTEX PHARMACEUTICALS INC N/A 114.30B
REGN REGENERON PHARMACEUTICALS 13.36 63.90B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.23B
ARGX ARGENX SE - ADR 98.17 35.18B
ONC BEIGENE LTD-ADR 6.16 25.99B
BNTX BIONTECH SE-ADR N/A 23.45B
NTRA NATERA INC N/A 22.01B
SMMT SUMMIT THERAPEUTICS INC N/A 19.34B
BIIB BIOGEN INC 8.06 18.69B

About CDIO

Company Profile

CDIO logo image Cardio Diagnostics Holdings, Inc. engages in the provision of medical diagnostic testing services. The company is headquartered in Chicago, Illinois and currently employs 13 full-time employees. The company went IPO on 2021-11-23. The firm develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.

Company Info

CARDIO DIAGNOSTICS HOLDINGS

311 W. Superior Street, Suite 444

Chicago ILLINOIS US

Employees: 8

CDIO Company Website

CDIO Investor Relations

Phone: 18552269991

CARDIO DIAGNOSTICS HOLDINGS / CDIO FAQ

What is the stock price of CARDIO DIAGNOSTICS HOLDINGS today?

The current stock price of CDIO is 4.31 USD. The price increased by 1.41% in the last trading session.


What is the ticker symbol for CARDIO DIAGNOSTICS HOLDINGS stock?

The exchange symbol of CARDIO DIAGNOSTICS HOLDINGS is CDIO and it is listed on the Nasdaq exchange.


On which exchange is CDIO stock listed?

CDIO stock is listed on the Nasdaq exchange.


What is CARDIO DIAGNOSTICS HOLDINGS worth?

CARDIO DIAGNOSTICS HOLDINGS (CDIO) has a market capitalization of 7.50M USD. This makes CDIO a Nano Cap stock.


How many employees does CARDIO DIAGNOSTICS HOLDINGS have?

CARDIO DIAGNOSTICS HOLDINGS (CDIO) currently has 8 employees.


What are the support and resistance levels for CARDIO DIAGNOSTICS HOLDINGS (CDIO) stock?

CARDIO DIAGNOSTICS HOLDINGS (CDIO) has a resistance level at 4.77. Check the full technical report for a detailed analysis of CDIO support and resistance levels.


Is CARDIO DIAGNOSTICS HOLDINGS (CDIO) expected to grow?

The Revenue of CARDIO DIAGNOSTICS HOLDINGS (CDIO) is expected to grow by 854.55% in the next year. Check the estimates tab for more information on the CDIO EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CARDIO DIAGNOSTICS HOLDINGS (CDIO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CARDIO DIAGNOSTICS HOLDINGS (CDIO) stock pay dividends?

CDIO does not pay a dividend.


When does CARDIO DIAGNOSTICS HOLDINGS (CDIO) report earnings?

CARDIO DIAGNOSTICS HOLDINGS (CDIO) will report earnings on 2025-08-12.


What is the Price/Earnings (PE) ratio of CARDIO DIAGNOSTICS HOLDINGS (CDIO)?

CARDIO DIAGNOSTICS HOLDINGS (CDIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.13).


What is the Short Interest ratio of CARDIO DIAGNOSTICS HOLDINGS (CDIO) stock?

The outstanding short interest for CARDIO DIAGNOSTICS HOLDINGS (CDIO) is 2.71% of its float. Check the ownership tab for more information on the CDIO short interest.


CDIO Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

CDIO Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CDIO. The financial health of CDIO is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CDIO Financial Highlights

Over the last trailing twelve months CDIO reported a non-GAAP Earnings per Share(EPS) of -3.13. The EPS decreased by -317.33% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -47.67%
ROE -51.46%
Debt/Equity 0.02
Chartmill High Growth Momentum
EPS Q2Q%-385%
Sales Q2Q%5800.82%
EPS 1Y (TTM)-317.33%
Revenue 1Y (TTM)-36.22%

CDIO Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to CDIO. The Buy consensus is the average rating of analysts ratings from 7 analysts.

For the next year, analysts expect an EPS growth of -224.15% and a revenue growth 854.55% for CDIO


Ownership
Inst Owners4.93%
Ins Owners4.52%
Short Float %2.71%
Short Ratio1.23
Analysts
Analysts82.86
Price TargetN/A
EPS Next Y-224.15%
Revenue Next Year854.55%